Extra potassium supplements, spironolactone or amiloride were given for 5 months to forty-nine patients with heart failure who were taking furosemide and were in a steady state. Plasma potassium increased with all three treatments but there was no significant increase in total body potassium or red cell potassium. These findings together with other studies suggest that patients with heart failure taking diuretics do not have a significant depletion of body potassium.
Introduction
Potassium depletion is generally accepted as one of the hazards of long-term treatment with potent diuretics in patients with heart failure, and these patients are therefore usually also given either potassium supplements or one of the potassiumsparing diuretics. The authors recently measured the total body potassium (TBK) of patients with chronic heart disease with a total body radiation counter . The TBK in the patients with heart disease was not significantly different from the TBK in a group of healthy subjects. Moreover, among the patients with heart disease there was no difference between those who were taking diuretics and those who were not, and in those on diuretics there was no difference between those taking small doses of potassium supplements and those taking large doses.
These findings contrasted with previous reports in the literature, and did not support the view that potassium depletion was a complication of long-term diuretic therapy. Nevertheless, it could be argued that a cross-sectional study is an insensitive approach since it depends on the comparison of a group of patients with a group of controls; a more sensitive approach would be to study serial changes in individual patients. Ideally such a study should be carried out from the time the patients start diuretics but this is difficult logistically and as far as the authors know it has not been done. Alternatively one can attempt to correct any deficit in body potassium in patients already established on treatment by giving extra potassium supplements or a potassium-retaining diuretic. If potassium depletion is present, these changes in treatment should cause an increase in TBK, even in a patient whose TBK is reduced but still lies within the normal range. Surprisingly this approach has only rarely been used in heart failure (De Deuchaisnes, Busset and Collet, 1961; White, 1970; Davidson and Gillebrand, 1973) .
A group of patients with heart failure have been studied who had been taking a constant dose of furosemide and potassium supplements for at least 6 months. The potassium supplements were either increased to 48 mmol/day or replaced by spironolactone or amiloride. The dose of furosemide was kept constant throughout the study. The potassium status of the three treatment groups was assessed at monthly intervals for 5 months after the change of treatment.
Patients
The patients in this study came from a larger cross-sectional study of patients with heart failure . Sixty-six patients who agreed to join the study were allocated to one of three treatment groups using random tables. Six patients were subsequently excluded from the potassium group because they were already taking 48 . Chest X-rays were taken at the beginning and end of the study. The total duration of the study was 18 months.
Results Table 2 shows that the plasma, electrolytes, urea and creatinine were the same on average in the three groups before treatment was changed. The average TBK differed between the groups, but there were also differences in age and weight. The observed TBK was compared with the TBK predicted from sex, age, weight, height and skin fold thicknesses 
Discussion
This longitudinal study was undertaken because the previous cross-sectional study of patients with heart failure had failed to detect large potassium deficits and was therefore at variance with numerous previous reports . The patients in the present study had apparent deficits which were similar to those in the previous study (50-200 mmol) . However, extra potassium, spironolactone or amiloride failed to raise the total body or red cell K despite a rise in plasma potassium, which makes it unlikely they were potassium depleted.
There have been several similar studies in heart failure in which either extra potassium or a potassium-sparing diuretic has been added to the diuretic [- The results from studies of potassium-sparing diuretics have been equally inconclusive. Davidson and Gillebrand (1973) gave amiloride for 6 months to twenty-four patients with heart failure stabilized on furosemide. There was a sustained rise in plasma potassium; Ke initially rose by 320 mmol but at 6 months was no greater than before the change in treatment. Nicholls, Espiner and Hughes (1976) studied eleven patients with heart failure for 2 months after substituting amiloride for potassium supplements. There was no change in plasma potassium or Ke. White (1969) reported that spironolactone prevented any fall in Ke in patients taking furosemide; Friis (1972) concluded that it did not increase Ke in patients with heart failure. There are several studies showing that spironolactone increases plasma potassium (George, Breckenridge and Dollery, 1973) .
The present study is thus in agreement with most reports from the literature. Extra potassium supplements or potassium-sparing diuretics can increase plasma potassium, but they do not influence body potassium. These drugs may therefore be unnecessary to maintain body potassium in heart failure during long-term diuretic treatment. Lawson Boddy and Gray (1976) gave twenty-one patients with heart failure diuretics but no potassium supplements for a year. There was a small fall in plasma potassium but no change in TBK.
Nevertheless, the general view is that patients with heart failure are depleted of potassium and that the depletion is related to the use of potent diuretics (Leading Article, 1977) . This view seems to be based on the numerous reports of low K, in patients with heart failure taking diuretics and the demonstration that these diuretics can increase the urine potassium and lower the plasma potassium. The authors have recently reviewed all published data on exchangeable potassium in patients with heart disease (Morgan, Burkinshaw and Davidson, 1978) . Although there was an apparent deficit of20-30% ofbody potassium, this deficit was no greater in the patients taking diuretics than in those who were not, and could be explained by the muscle wasting which happens in chronic heart disease.
The findings in the present study, the authors' previous study , the study of Lawson et al. (1976) and the authors' review of the literature (Morgan et al., 1978) lead the authors to conclude that there is no true potassium depletion in patients with heart disease, even those taking diuretics. The only reason for treating patients with potassium supplements or potassium-sparing agents is to prevent or treat a low plasma potassium. 
